FAQ

3,4-dihydroxybenzohydroxamic acid

Known as: Benzamide, N,3,4-trihydroxy-, Didox, N,3,4-trihydroxybenzamide 
A ribonucleotide reductase inhibitor with activity against retroviruses. Didox inhibits retrovirus replication by depleting the deoxynucleotides… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1982-2017
02419822017

Related topics

Related topics

4 relations

Broader (3)

Antineoplastic AgentsEnzyme InhibitorsHydroxamic Acids

Narrower (1)

VF 147

Related mentions per year

Related mentions per year

1946-2018
19401960198020002020
3,4-dihydroxybenzohydroxamic acid
Antineoplastic Agents
Enzyme Inhibitors
Hydroxamic Acids
VF 147

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Didox (3,4-dihydroxybenzohydroxamic acid) suppresses IL-33-induced cytokine production in primary mouse mast cells.
While IgE is considered the primary mediator of mast cell activation, IL-33 contributes substantially in asthma, allergic… (More)
Is this relevant?
2015
2015
3,4-Dihydroxy-benzohydroxamic acid (Didox) suppresses pro-inflammatory profiles and oxidative stress in TLR4-activated RAW264.7 murine macrophages.
Didox (3,4-dihydroxy-benzohydroxamic acid), is a synthetic ribonucleotide reductase (RR) inhibitor derived from polyhydroxy… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 4
Is this relevant?
2006
2006
Robust vascular protective effect of hydroxamic acid derivatives in a sickle mouse model of inflammation.
OBJECTIVE Clinically, the vascular pathobiology of human sickle cell disease includes an abnormal state of chronic inflammation… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants.
OBJECTIVE To determine the role of oxidative stress in mediating HIV dementia and to identify novel therapeutic compounds that… (More)
  • figure 2
  • figure 1
  • figure 5
  • figure 6
Is this relevant?
2003
2003
Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells
Temozolomide (TMZ), an oral alkylating agent with good penetration of the blood-brain barrier, has shown efficacy in the… (More)
  • figure 1
  • table 1
  • figure 2
Is this relevant?
2001
2001
Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox.
OBJECTIVE Amidox and didox are two polyhydroxy-substituted benzohydroxamic acid derivatives that belong to a new class of… (More)
Is this relevant?
1998
1998
Iron binding capacity of didox (3,4 dihydroxybenzohydroxamic acid) and amidox (3,4 dihydroxybenzamidoxime) two inhibitors of the enzyme ribonucleotide reductase.
Ribonucleotide reductase is the rate limiting enzyme of deoxynucleoside triphosphate synthesis and is considered to be an… (More)
Is this relevant?
1997
1997
Iron binding capacity of didox (3,4-dihydroxybenzohydroxamic acid) and amidox (3,4-dihydroxybenzamidoxime) new inhibitors of the enzyme ribonucleotide reductase.
Ribonucleotide reductase is the rate limiting enzyme of deoxynucleoside triphosphate synthesis and is considered to be an… (More)
Is this relevant?
1991
1991
Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime.
Didox and Amidox inhibit L1210 cell growth in culture. At least one of the mechanisms in the mode(s) of action of the compounds… (More)
Is this relevant?
1988
1988
A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor.
A phase 1 study of a new ribonucleotide reductase inhibitor, didox, was performed by administration of escalating doses of the… (More)
  • table II
  • table I
  • figure I
  • figure 2
Is this relevant?